Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases

Weisser B, Wassmann S, Predel HG, Schmieder R, Gillessen A, Wilke T, Blettenberg J, Randerath O, Mevius A, Böhm M (2024)

Publication Type: Journal article

Publication year: 2024

Journal

European Heart Journal - Cardiovascular Pharmacotherapy Oxford University Press

Book Volume: 10

Pages Range: 686-693

Journal Issue: 8

DOI: 10.1093/ehjcvp/pvae059

Abstract

Aims: Our study aimed to assess whether a single pill concept (SPC) is superior to a multi-pill concept (MPC) in reducing cardiovascular (CV) events, all-cause death, and costs in CV patients. Method and results: Anonymized medical claims data covering 2012-2018, including patients with hypertension, dyslipidaemia, and CV diseases who started a drug therapy either as SPC or identical MPC were analysed after 1:1-propensity score matching. Hospitalizations with predefined CV events, all-cause mortality, and costs were studied in 25 311 patients with SPC and 25 311 patients with MPC using incidence rate ratios (IRRs) and non-parametric tests for continuous variables. IRRs were significantly lower for SPC: stroke (IRR = 0.77; 95% CI 0.67-0.88; P < 0.001), transitory ischaemic attack (IRR = 0.61; 95% CI 0.48-0.78; P < 0.001), myocardial infarction (IRR = 0.76; 95% CI 0.63-0.90; P = 0.0016), coronary artery disease (IRR = 0.66; 95% CI 0.57-0.77; P < 0.001), heart failure (IRR = 0.59; 95% CI 0.54-0.64; P < 0.001), acute renal failure (IRR = 0.54; 95% CI 0.56-0.64; P < 0.001), all cause hospitalization (IRR = 0.72; 95% CI 0.71-0.74; P < 0.001), CV hospitalization (IRR = 0.63; 95% CI 0.57-0.69; P < 0.001), and all-cause mortality (IRR = 0.62; 95% CI 0.57-0.68; P < 0.001). Mean time to first events and time to death were also in favour of SPC. Mean total costs were 4708€ for SPC vs. 5.669€ for MPC, respectively (mean ratio 0.830, P < 0.001). Conclusion: SPC is associated with lower incidence rates of CV events, time to CV events, and all-cause death, and is superior regarding pharmacoeconomic parameters and should therefore become standard of care to improve outcomes and reduce healthcare costs.

Authors with CRIS profile

Roland Schmieder Professur für Innere Medizin (Nephrologie)

Involved external institutions

Universitätsklinikum des Saarlandes (UKS) DE Germany (DE) Christian-Albrechts-Universität zu Kiel DE Germany (DE) LMU Klinikum DE Germany (DE) Deutsche Sporthochschule Köln DE Germany (DE) Herz-Jesu-Krankenhaus Hiltrup DE Germany (DE) Institut für Pharmakoökonomie und Arzneimittellogistik e.V. (IPAM) DE Germany (DE) APONTIS PHARMA GmbH & Co. KG DE Germany (DE)

How to cite

APA:

Weisser, B., Wassmann, S., Predel, H.G., Schmieder, R., Gillessen, A., Wilke, T.,... Böhm, M. (2024). Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases. European Heart Journal - Cardiovascular Pharmacotherapy, 10(8), 686-693. https://doi.org/10.1093/ehjcvp/pvae059

MLA:

Weisser, Burkhard, et al. "Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases." European Heart Journal - Cardiovascular Pharmacotherapy 10.8 (2024): 686-693.

BibTeX: Download